A compound score to screen patients with hereditary transthyretin amyloidosis.

Stefano TozzaDaniele SeveriEmanuele SpinaAndrea Di PaolantonioAniello IovinoValeria GuglielminoFrancesco ArutaMaria NolanoMario SabatelliLucio SantoroMarco LuigettiFiore Manganelli

Published in: Journal of neurology (2022)

Our study demonstrated that our compound score with cut-off ≥ 5 allows to discriminate ATTRv patients among subject affected by axonal polyneuropathy with a sensitivity > 95%. Thus, our compound score is a quick, easy and effective screening tool.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
spinal cord injury
peritoneal dialysis
prognostic factors
multiple myeloma
patient reported outcomes